Import:3H Biomedizin: Unterschied zwischen den Versionen
en>TLEG (←Created page with '{{Infobox Company | | company_name = 3H Biomedical | company_type = Limited | foundation = 2004 | location = Uppsala, Sweden | key_people = Mallen Huang ([[...') |
(Edit of spelling...) |
||
| Zeile 11: | Zeile 11: | ||
| intl = yes | | intl = yes | ||
}} | }} | ||
'''3H Biomedical''' is a [[biotechnology]] company based in [[Uppsala]], [[Sweden]], where it operates out of Uppsala Science Park. The company develops, produces and markets cell-based tools for [[life science]], [[tissue engineering]], [[drug discovery]] and cosmetics testing. 3H | '''3H Biomedical''' is a [[biotechnology]] company based in [[Uppsala]], [[Sweden]], where it operates out of Uppsala Science Park. The company develops, produces and markets cell-based tools for [[life science]], [[tissue engineering]], [[drug discovery]] and cosmetics testing. 3H Biomedical also offers contract research services. The company’s research and development focus lays in the fields of [[Immunotherapy|cell immune therapy]] and [[Stem cell treatments|adult stem cell therapy]].<ref>http://yellowpages.scanbalt.org/uppsala/Ups_search.php?company=12875</ref> | ||
==History== | ==History== | ||
Version vom 24. Juni 2009, 10:23 Uhr
Vorlage:Infobox Company 3H Biomedical is a biotechnology company based in Uppsala, Sweden, where it operates out of Uppsala Science Park. The company develops, produces and markets cell-based tools for life science, tissue engineering, drug discovery and cosmetics testing. 3H Biomedical also offers contract research services. The company’s research and development focus lays in the fields of cell immune therapy and adult stem cell therapy.[1]
History
3H Biomedical was founded in 2004[2] as a spring off from Uppsala University[3]. In the same year 3H Biomedical was awarded with the foundation of innovation of Handelsbanken Uppsala award. The award was presented for commercially interesting research in the field of DNA-based vaccines.[4] The company started out marketing and selling primary cells, and has since extended its portfolio with cell chips, RNA, DNA, recombinant proteins, blood serum and plasma, vectors for genetic modification and cell-based assays.[5]